The Prevalence of Thiamin Deficiency in Hospitalized Patients With Congestive Heart Failure  by Hanninen, Stacy A. et al.
T
i
S
M
T
T
c
c
s
p
l
c
i
v
w
e
o
i
(
t
h
T
‡
O
L
S
C
f
D
2
Journal of the American College of Cardiology Vol. 47, No. 2, 2006
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Phe Prevalence of Thiamin Deficiency
n Hospitalized Patients With Congestive Heart Failure
tacy A. Hanninen, RD, MSC,*§ Pauline B. Darling, PHD, RD,†§
ichael J. Sole, MD, FRCPC, FACC,** Aiala Barr, PHD,¶ Mary E. Keith, PHD‡#
oronto, Ontario, Canada
OBJECTIVES The purpose of this study was to determine the prevalence of thiamin deficiency (TD) in a
cross section of hospitalized congestive heart failure (CHF) patients and to investigate factors
that contribute to its development.
BACKGROUND Thiamin deficiency manifests as symptoms of CHF and, therefore, may worsen existing heart
failure. Congestive heart failure patients may be at increased risk for TD as a result of
diuretic-induced urine thiamin excretion, disease severity, malnutrition, and advanced age.
METHODS Erythrocyte thiamin pyrophosphate concentrations, using high-performance liquid chroma-
tography, were measured in 100 CHF patients and compared to 50 control subjects. Variables
including diuretics (type and dose), left ventricle dysfunction, New York Heart Association
functional classification, creatinine clearance, thiamin intake (diet and supplements), malnu-
trition, appetite ratings, and age were related to TD using univariate statistics and multiple
logistic regression analysis.
RESULTS Thiamin deficiency was more prevalent in CHF patients (33%) compared to control subjects
(12%) (p  0.007). Thiamin deficiency was related to urine thiamin loss (p  0.03), non-use
of thiamin-containing supplements (p  0.06), and preserved renal function (p  0.05).
Increased urinary thiamin loss (g/g creatinine) was found to be the only significant positive
predictor of thiamin status on multiple logistic regression analysis (p  0.03).
CONCLUSIONS One-third of hospitalized CHF patients were TD. In contrast to previous studies, increased
urinary losses of thiamin were predictive of improved thiamin status. Thiamin supplemen-
tation may be protective against TD in the clinical setting. Future studies are warranted to
determine if thiamin supplementation improves thiamin status and disease severity in CHF
patients. (J Am Coll Cardiol 2006;47:354–61) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.060Cardiology Foundation
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ahiamin, a water-soluble B-complex vitamin, functions as a
oenzyme in macronutrient oxidation and the production of
ellular adenosine tri-phosphate (1). Mammals cannot bio-
ynthesize or significantly store thiamin and thus are de-
endent on continual ingestion. Thiamin deficiency (TD)
argely manifests as neurologic (dry beriberi) or cardiovas-
ular (wet beriberi) disease. Thiamin-deficient heart disease
s characterized by sodium and water retention, peripheral
asodilatation, and myocardial failure. Therefore, TD
ould be expected to worsen symptoms in the setting of
stablished congestive heart failure (CHF) (1).
Numerous factors have been reported to increase the risk
f developing TD in CHF patients, including diuretic-
nduced urine thiamin excretion (2–5), severe heart failure
6), malnutrition (6,7), advanced age, and frequent hospi-
alizations (5,8–12). The prevalence of TD in CHF patients
as been reported to range from 3% to 91% (2,5–7,12,13 ).
rials of thiamin supplementation, although clinically im-
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Division of Cardiovascular and Thoracic Surgery, St. Michael’s Hospital, Toronto,
ntario, Canada; §Department of Nutritional Sciences, Heart and Stroke/Richard
ewar Centre of Excellence, ¶Department of Public Health, and the #Department of
urgery, University of Toronto, Toronto, Ontario, Canada; and the **Division of
ardiology, University Health Network, Toronto, Ontario, Canada. This project was
unded by a research grant from the Canadian Foundation for Dietetic Research,
ietitians of Canada, Toronto, Ontario.i
Manuscript received December 15, 2004; revised manuscript received August 9,
005, accepted August 23, 2005.ortant, have been hampered by their small sample sizes, use
f indirect measures of thiamin status, and exclusion of
atients with less severe disease and those on diuretics other
han loop diuretics (2,8,11–17). Therefore, the objective of
his study was to determine the prevalence of TD in a large
ross section of hospitalized CHF patients.
ETHODS
tudy design. In this prospective, cross-sectional, observa-
ional study, the prevalence of TD in 100 consecutive
atients admitted to the hospital with a primary diagnosis
f CHF was determined and compared with that of 50
atched control subjects.
HF PATIENTS AND CONTROL SUBJECT SELECTION. Diag-
osis of CHF was made by the attending physician and
onfirmed based on a left ventricular (LV) ejection fraction
EF) 50%, according to a two-dimensional echocardio-
ram, or a normal LV function (EF 50%) with classic
HF symptoms according to Framingham criteria (18).
ubjects were excluded if they were being treated with
igh-dose thiamin supplements (200 mg/day) for alcohol
buse or were unable to give informed consent.
Age- (within five years) and gender-matched control
ubjects were recruited into the study through hospital
dvertisement in a 2:1 ratio. Control subjects were excluded
f they had any known condition that may affect thiamin
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January 17, 2006:354–61 Thiamin Deficiency in CHFtatus or were taking thiamin-containing supplements. Ap-
roval for this study was obtained from the St. Michael’s
ospital Research Ethics Board.
tudy procedures. COLLECTION OF MEDICAL INFORMA-
ION. Demographic and clinical information (including
edication use) was recorded from the medical chart. Oral
iuretics were reported as the average daily dose, whereas
ntravenous diuretics were recorded as twice the actual dose
iven in order to be equivalent to an oral dose (19).
easurement of thiamin status. ERYTHROCYTE THIAMIN
YROPHOSPHATE ANALYSIS. Within 48 h of admission,
asting blood samples were collected from CHF patients.
lood samples from control subjects were also obtained
ollowing an overnight fast. Blood was collected in evacu-
ted tubes with ethylenediamine-tetraacetic acid and cen-
rifuged (within 30 min) for 10 min at 3,000 rpm. Eryth-
ocytes were washed and stored at 70°C for later analysis.
rythrocyte thiamin pyrophosphate (TPP) was determined
sing high-performance liquid chromatography (HPLC) on
n amino column (supelcosil-LC-NH2, 5  particle size,
5.0 cm  4.6 mm, Supelco product, Sigma Corp., To-
onto, Ontario, Canada) according to the methods of
arnock (20). The fluorescence detector was set at an
xcitation wavelength of 360 nm and an emission wave-
ength of 440 nm. The coefficient of variation of samples
as 5.4%. Thiamin deficiency was defined as an erythrocyte
PP 78 ng/ml packed cells based upon the correlation
etween erythrocyte TPP concentration and the TPP effect,
hich indicates TD in alcoholic patients (8,21).
able 1. Characteristics of Control Subjects and CHF Patients
t Hospital Admission
Characteristics
CHF
Patients
(n  100)
Control
Patients
(n  50) p Value
ender, n (%)
Male 58 (58) 24 (48) 0.246
Female 42 (42) 26 (52)
ge, yrs (mean SD) 67.1 (10.1) 61.1 (11.1) 0.001
se of B1 supplements*, n (%) 21 (21) None
se of other supplements†, n (%) 41 (41) 9 (18) 0.001‡§
CHF patients taking thiamin-containing supplements (e.g., multivitamin or
-complex) before admission and/or during hospital admission. †Includes vitamin,
ineral, and herbal supplements, other than thiamin-containing supplements. ‡Sig-
Abbreviations and Acronyms
CHF  congestive heart failure
CI  confidence interval
EAR  estimated average requirement
EF  ejection fraction
HPLC  high-performance liquid chromatography
LV  left ventricular
SGA  subjective global assessment
TD  thiamin deficiency
TPP  thiamin pyrophosphateificant at p value 0.05. §Fisher’s exact test.
CHF  congestive heart failure.
*RINE COLLECTION. Twenty-four hour urine collections
ere initiated within 48 h of admission. The urine was
mmediately transferred to 3-l amber bottles containing 20
l acetic acid and kept at 4°C, where the volume and
reatinine were measured within 24 h; a 50-ml aliquot was
tored at 70°C for the determination of urine thiamin
oncentration.
able 2. Characteristics of CHF Patients at Hospital Admission
Characteristics
CHF Patients
(n  100)
edical history
Diabetes, n (%) 34 (34)
Renal insufficiency*, n (%) 82 (88)
ild to moderate malnutrition†, n (%) 49 (50)
oor/fair appetite‡, n (%) 48 (48)
hiamin intake§, mg/day, mean (SD) 1.60 (0.64)
tiology of CHF
CAD 40 (40)
Valve disease 18 (18)
Hypertension 3 (3)
Combination (CAD/valve) 11 (11)
Cardiomyopathy 28 (28)
YHA functional classification, n (%)
Class I 6 (6)
Class II 18 (18)
Class III 43 (43)
Class IV 32 (32)
V function, n (%)
Grade I (EF 50%) 21 (21)
Grade II (EF  35%–49%) 26 (26)
Grade III (EF  25%–35%) 27 (27)
Grade IV (EF 25%) 26 (26)
Renal insufficiency is defined as corrected creatinine clearance 1.24 ml/s/SA, n 
3. †Subjective global assessment score B (n  98), score C (n  1). ‡Self-reported
ppetite rating scale. §Thiamin intake determined by food frequency questionnaire.
NYHA functional classification completed in 99 subjects.
CAD  coronary artery disease; EF  ejection fraction; LV  left ventricle;
YHA  New York Heart Association; other abbreviations as in Table 1.
able 3. Medication Use of CHF Patients
Medication, n (%)
CHF Patients
(n  100)
re-admission diuretics
Furosemide 80 (80)
Spironolactone* 18 (18)
Metolazone* 9 (9)
ospital diuretics
Furosemide 99 (99)
Spironolactone* 28 (28)
Metolazone* 15 (15)
CE inhibitor 61 (61)
eta-blocker 58 (58)
spirin 48 (48)
itrates/vasodilators 40 (40)
ipid-lowering therapy 48 (48)
nticoagulant 43 (43)
igoxin 33 (33)
alcium-channel blocker 26 (26)
nti-arrhythmic 21 (21)
ngiotensin receptor blockades 9 (9)
nsulin 13 (13)CHF patients were also on furosemide.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure.
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Thiamin Deficiency in CHF January 17, 2006:354–61Urine thiamin was analyzed by HPLC according to the
ethods developed by Botticher and Botticher (22) using
reshly prepared thiamin standards (2 to 30 ng/ml, Sigma
orp.) in 0.1 mol sulphuric acid. Urine thiamin concentra-
ion (24 h) was corrected for renal function by calculating urine
hiamin as g/g creatinine. Corrected creatinine clearance
ml/s/SA) was determined using a standard equation (23).
UTRITIONAL ASSESSMENT. A trained registered dietitian
etermined nutrition status of all CHF patients using
ubjective global assessment (SGA) (24). Appetite was
ssessed using a self-reported rating scale (7).
IETARY THIAMIN INTAKE. Since biochemical signs of TD
ccur within two to three weeks of a TD diet, the usual daily
hiamin intake of CHF patients from food and supplements
as estimated using a semi-quantitative food frequency
uestionnaire modified from Block 2000 for the month
efore hospitalization (25,26). Thiamin intake was deter-
ined using the Nutriwatch nutrient analysis program
© 1981 to 2001, Elizabeth Warwick, Long Creek, PO Box
06, Cornwall, Prince Edward Island, Canada C0A 1H0),
igure 1. The distribution of erythrocyte thiamin pyrophosphate (TPP) i
Table 4. Prevalence of TD in CHF Patients a
CHF
Prevalence of TD*, n (%), 95% CI 33 (33)
Prevalence of TD†, n (%), 95% CI 29 (37)
*Includes all CHF patients, n  100. †Excludes CHF patient
admission, n  78. Thiamin deficiency defined as erythrocyt
at p value 0.05.
CHF  congestive heart failure; CI  confidence intervrade 1 or 2  ejection fraction (EF) 35%, grade 3 or 4  EF 35%. The d
ells (RBCs). Congestive heart failure patients with a TPP below this cut poinhich contained the 1997 Canadian Nutrient File. Ade-
uacy of thiamin intake was determined by comparing the
stimated intake to the estimated average requirement
EAR) (17).
tatistical analysis. Continuous data were expressed as
edians (range) and categorical data as frequencies and
ercentages unless otherwise noted. Comparisons between
wo groups for categorical data were completed using either
he Pearson chi-square test or the Fisher exact test, when
ounts per cell were 5. The Mann-Whitney U test was
sed for comparisons between continuous variables.
Predictor variables for TD were determined using
ogistic regression analysis. All variables found significant
n univariate logistic regression with a p 0.2 were
onsidered for multiple regression analysis (27). Highly
ntercorrelated variables were identified by correlation
atrix, and only one of these variables was entered into
he multiple regression model using the backward selec-
ion method. All statistical analyses were performed using
he SPSS for Windows, Version 9.0 software (Statistical
ackage for the Social Sciences, Chicago, Illinois). The
gestive heart failure (CHF) patients by grade of left ventricular function.
ontrol Subjects
ents Control Subjects p Value
–41% 6 (12), 5%–20% 0.007‡
–45% 6 (12), 5%–20% 0.002‡
g thiamin-containing supplements before or during hospital
concentration 78 ng/ml packed erythrocytes. ‡Significant
 thiamin deficiency; TPP  thiamin pyrophosphate.n connd C
Pati
, 26%
, 30%
s takin
e TPPashed line is drawn at an erythrocyte TPP of 78 ng/ml packed red blood
t were considered thiamin deficient (TD).
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January 17, 2006:354–61 Thiamin Deficiency in CHFvalues were two-tailed, and a p value 0.05 was
onsidered statistically significant.
ESULTS
tudy population. One hundred CHF patients were re-
ruited into the study from April 2001 to June 2002 (Tables 1
nd 2). Patients represented a community population ad-
itted to hospital, not necessarily under the care of a
ardiologist. Despite matching, CHF patients were signif-
cantly older than control subjects. The main cause of CHF
as coronary artery disease. Twenty-one CHF patients took
hiamin-containing supplements, which were predomi-
ately multivitamin/mineral supplements with a thiamin
ontent ranging from 1.5 to 2.25 mg/day. Approximately
ne-third of CHF patients had diabetes mellitus, and the
ajority had decreased renal function (corrected creatinine
learance 1.24 ml/s/SA). Although 50% of CHF patients
ere malnourished (using SGA) and reported decreased
ppetites, the mean intake of thiamin was adequate com-
ared to the EAR.
iuretic use. The median dose of furosemide at home
as 60 mg/day (10 to 360 mg/day), which had been taken
or 14 months (10 to 300 months) (Table 3). Twenty-
our patients (30%) were prescribed multiple diuretics.
revalence of TD and thiamin status. One-third of
HF patients (33%) were found to be TD, which was
ignificantly higher than control subjects (p  0.007)
Table 4, Figs. 1 and 2). This difference was strengthened
hen supplement users were excluded (37.2% [95%
onfidence interval (CI) 30% to 45%] vs. 12.2% [95% CIigure 2. The distribution of erythrocyte TPP in healthy control patients. The d
alues below this cut point were considered TD. Abbreviations as in Figure 1.% to 20%], respectively, p  0.002) (Fig. 3). Although
here was no significant difference in erythrocyte TPP
etween CHF patients and control subjects (87 [range 45
o 222] ng/ml vs. 97 [range 60 to 203] ng/ml, p  0.109,
espectively), when supplement users were excluded,
rythrocyte TPP concentrations were significantly lower
n the CHF group (85 [range 45 to 203] ng/ml vs. 97
range 60 to 203) ng/ml, p  0.014, respectively). Urine
hiamin excretion was 252 g/g creatinine (60 to 8,640)
n CHF patients, which was within the previously re-
orted normal range (22) (Fig. 4). Forty percent of
atients with grade III/IV LV function were TD com-
ared to 25% of those with grade I/II ventricular function
p  0.1); this difference was accentuated when supple-
ent users were excluded (49% vs. 24% respectively, p 
.03). The CHF patients with LV dysfunction were
ounger (p  0.018) and mostly male (75%); had a lower
ody mass index (p  0.001), more malnutrition (p 
.01), higher creatinine (p  0.023), and lower TPP (p 
.07); and stayed in hospital longer (p  0.06) than those
ith grade I/II ventricles.
nivariate analysis of determinants of TD. Pre-
dmission spironolactone use, preserved renal function, and
on-use of thiamin-containing supplements were signifi-
antly associated with TD (p  0.05). Left ventricular
unction, poor and fair appetite ratings, mild to moderate
alnutrition (SGA score B or C), and inadequate thiamin
ntake tended to be associated with TD (Table 5).
ultivariate analysis of determinants of TD. As many
ariables were intercorrelated, representative variables wereashed line is drawn at TPP of 78 ng/ml packed RBCs. Controls with TPP
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Thiamin Deficiency in CHF January 17, 2006:354–61igure 3. The distribution of erythrocyte TPP in CHF patients according to use of thiamin-containing multivitamins. The dashed line is drawn at an
rythrocyte TPP of 78 ng/ml packed RBCs. Congestive heart failure patients with a TPP below this cut point were considered TD. Abbreviations as in
igure 1.igure 4. The distribution of urinary losses of thiamin per gram of creatinine by left ventricular (LV) function grade. Grade 1 or 2  EF 35%, grade
or 4 EF35%. The dashed line indicates urine thiamin loss of 66 g/g creatinine, the level above which has been proposed to represent normal urinary
hiamin excretion (2).
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January 17, 2006:354–61 Thiamin Deficiency in CHFelected for multivariate analysis. Thiamin-containing sup-
lement use was chosen over other variables related to
hiamin intake (SGA, intake  EAR, appetite rating) as it
ad the strongest relationship with TD (Table 5). Similarly,
rine thiamin excretion (g/g creatinine) reflected the most
ccurate estimate of thiamin excretion. Corrected creatinine
learance was unrelated to any other variable and therefore
as entered into multivariate analysis (Table 6). Of these
hree variables, urine thiamin excretion was found to be the
trongest negative predictor of TD (p  0.025 [95% CI
.94 to 0.99]) (Table 6).
ISCUSSION
ne-third of hospitalized CHF patients at our institution
ere found to have erythrocyte TPP concentrations indic-
tive of TD. This study represents a large, typical cross
ection of hospitalized patients in various stages of CHF
nd on varying types and doses of diuretics using a direct
easure of thiamin status.
Previous studies have focused on diuretic-induced urine
hiamin excretion as the main cause of TD in CHF patients
2–5). Increased urinary losses of thiamin in response to
iuretic therapy have been observed in both normal and TD
ats (3,28), in healthy human volunteers (4), and in CHF
atients on high doses of furosemide (2,5). Surprisingly, we
Table 5. Univariate Analysis of the Relationship Be
Dependent Variable*
Variable Wald
Urine thiamin, g/g creatinine
Thiamin supplement use
Corrected creatinine clearance 1.24 ml/s/SA
Pre-admission spironolactone
LV function (grade III–IV)
Thiamin intake  EAR
Mild/moderate malnutrition
Poor/fair appetite
Urine volume, l/24 h
Age, yrs
Male gender
Diabetes
Furosemide use
Furosemide dose (80 mg/day)
Multiple diuretic use (1 diuretic)
Metolazone use
*The dependent variable measures TD as erythrocyte TPP 78 ng/
†Significant at p value  0.05.
EAR  estimated average requirement; OR  odds ratio; othe
Table 6. Multiple Logistic Regression Analysis
Independent Variables Coefficient
Variables included in model
Urine thiamin g/g creatinine 0.3423
Variables excluded by model
Thiamin supplement use 0.6057
Creatinine clearance, 1.24 ml/s/SA 0.9668
*Significant at p  0.05. The dependent variable measures th
 1 and erythrocyte TPP 78 ng/ml  0.
Abbreviations as in Tables 1 to 5.ailed to find a significant relationship between TD and
urosemide dose, urine volume, or urine thiamin excretion.
n fact, urine thiamin excretion was the only significant
ositive predictor of thiamin status, suggesting that in-
reased urine thiamin excretion independently predicts bet-
er thiamin status. Since studies in healthy adults suggest
hat urine thiamin excretion is positively correlated with
ietary thiamin intake and blood thiamin concentrations,
ur urinary thiamin excretion may simply reflect the amount
f thiamin consumed in the diet and supplements (Fig. 5)
1,25,29,30). Supporting this relationship is the observed
rend between TD and inadequate thiamin intakes, a
nding previously observed in CHF patients as well as in
ealthy volunteers following a thiamin-restricted diet
6,25). This finding is not surprising, as 50% of our CHF
atients were malnourished and had decreased appetites.
ultivitamin vitamin supplement use was found to be
rotective against TD, suggesting that even small doses of
hiamin (1.5 mg/day) may be effective in reducing rates of
D. Finally, the finding that decreased renal function was
ignificantly associated with better thiamin status in CHF
atients implies that decreased renal function may prevent
xcessive thiamin loss, thereby protecting against TD.
urther research is required to confirm our findings regard-
ng renal function and TD. The significant relationship
Study Variables and TD as the
-Square OR (95% CI) p Value
3 0.97 (0.94–0.99) 0.025†
2 0.28 (0.08–1.04) 0.057
0 0.30 (0.09–1.02) 0.055
7 2.4 (0.85–6.83) 0.096
1 1.91 (0.81–4.50) 0.14
1 2.63 (0.74–9.41) 0.14
0 1.85 (0.79–4.32) 0.16
2 1.92 (0.81–4.50) 0.14
0 0.68 (0.39–1.21) 0.20
5 1.29 (0.85–1.97) 0.23
0 1.72 (0.72–4.1) 0.22
9 0.63 (0.25–1.57) 0.32
2 1.62 (0.53–4.91) 0.40
0 0.63 (0.21–1.85) 0.40
3 1.51 (0.59–3.85) 0.39
1 0.55 (0.11–2.82) 0.48
iamin deficient  1, and non-thiamin deficient  0.
viations as in Tables 1 to 4.
Wald Chi-Square OR (95% CI) p Value
5.03 0.97 (0.94–0.99) 0.03*
0.45 0.55 (0.09–3.17) 0.5
2.02 0.38 (0.10–1.44) 0.15
deficiency with erythrocyte TPP 78 ng/ml, indicating TDtween
Chi
5.0
3.6
3.7
2.7
2.2
2.2
2.0
2.2
1.7
1.4
1.5
0.9
0.7
0.7
0.7
0.5
ml. ThB
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Thiamin Deficiency in CHF January 17, 2006:354–61etween TD and spironolactone use before hospitalization
upports previous findings linking TD and increased disease
everity (5,12,31). Furthermore, the increased prevalence of
D in patients with LV dysfunction, despite similar intakes
f dietary thiamin, suggests that these patients may repre-
ent a higher-risk population for TD.
Our sample size may have been inadequate to determine
ll the significant relationships between factors and TD, as
he sample size was based on an expected prevalence of TD.
n addition, urinary thiamin data from control subjects was
ot collected. Finally, given the nature of our population, we
ere unable to use the most accurate estimate of usual food
ntake and were limited to using a semi-quantitative food
requency questionnaire to estimate usual thiamin intake.
onclusions. This is the largest study of the prevalence of
D in a cross section of typical hospitalized CHF patients
ith varying degrees of disease severity and taking a variety
f diuretics. We found that the prevalence of TD in CHF
atients in an acute care hospital is high (30%). Factors
ignificantly related to TD included pre-admission spirono-
actone use, preserved renal function, and non-use of
hiamin-containing supplements. These factors could be
sed to identify hospitalized CHF patients at risk for TD.
n contrast to previous studies, we found that increased
rinary thiamin excretion predicted improved thiamin status
ather than TD in hospitalized CHF patients. The protec-
ive effect of supplements with relatively low thiamin con-
ent suggests that routine thiamin supplementation may
reserve thiamin status. This should be considered as
Figure 5. The relationship between estimated dailyoutine treatment for hospitalized CHF patients. Futuretudies are warranted to determine the possible benefits of
hiamin supplementation in CHF patients.
eprint requests and correspondence: Dr. Mary E. Keith,
esearch Associate, Cardiovascular and Thoracic Surgery, 8 Bond
ing, Suite 003J, St. Michael’s Hospital, MB5 1W8. E-mail:
eithm@smh.toronto.on.ca.
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